Therapy‐related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks
Malcolm A. Smith(National Cancer Institute), Richard S. Ungerleider(Theradex Oncology (United States)), Larry Rubinstein(National Cancer Institute)
Cited by 178
Related Papers
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
The genomic landscape of pediatric acute lymphoblastic leukemia
|Nature Genetics|2022|394